Dec 05, 2019 / 04:00PM GMT
Ron Petersen -
Well, good morning, everyone. Thank you so much for coming out to hear what I think is going to be a very enlightening presentation this morning and subsequent discussion. My name is Ron Petersen, and I'm a neurologist and Director of the Alzheimer's Disease Research Center at the Mayo Clinic in Rochester, Minnesota. I am accompanied by an esteemed panel, whom I will introduce in just a moment.
First of all, I'd like to thank the CTAD Leadership Committee for allowing us this presentation this morning. So Paul, Bruno, Jacques and Mike, thanks very much for this because I think this is a pivotal time for us in the field. And I think what we're going to discuss this morning is going to be very, very important. I'd like to introduce our panelists. First, we have Samantha Budd Haeberlein, who's the Vice President for Clinical Development at Biogen, and she will be presenting the data; next is Paul Aisen, who's the Director of the Alzheimer's Treatment Research Institute of University of Southern California, here in San Diego; Sharon Cohen, a behavioral neurologist from Toronto, who is a
Biogen Inc Aducanumab Phase 3 Topline Results Transcript
Dec 05, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers